FDA Approves GSK's Ojjaara (Momelotinib) For Intermediate Or High-risk Myelofibrosis In Adults With Anemia As The Only Approved Medicine For Both Newly Diagnosed And Previously Treated Myelofibrosis Patients
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved GSK's Ojjaara (Momelotinib) for intermediate or high-risk myelofibrosis in adults with anemia. This makes Ojjaara the only approved medicine for both newly diagnosed and previously treated myelofibrosis patients.
September 18, 2023 | 8:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK's Ojjaara has been approved by the FDA for intermediate or high-risk myelofibrosis in adults with anemia. This could potentially increase GSK's market share in the myelofibrosis treatment market.
The FDA approval of Ojjaara (Momelotinib) for intermediate or high-risk myelofibrosis in adults with anemia could potentially increase GSK's market share in the myelofibrosis treatment market. This is because Ojjaara is now the only approved medicine for both newly diagnosed and previously treated myelofibrosis patients, which could lead to increased sales for GSK.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100